This review compared venous thromboembolism rates with twice-or three-times-daily unfractionated heparin regimens in hospitalised patients. The authors concluded that more frequent dosing reduces thromboembolism rates, but increases the risk of bleeding, and treatment should therefore depend on the patients' underlying risk for these factors. These conclusions might not be reliable as they are based on indirect comparisons of variable studies.
Study selection Study designs of evaluations included in the review
To be eligible, the studies had to be randomised controlled trials (RCTs).
Specific interventions included in the review
To be eligible, studies needed to compare subcutaneously dosed unfractionated heparin with placebo or a suitable control (which was not further defined). Heparin had to be dosed at 5,000 U either two or three times a day. Of the 12 included studies, five assessed heparin given twice daily and seven assessed heparin given three times daily. Comparison groups included identical placebo (2 studies), low molecular weight heparin (5 studies), flubiprofen (1 study) and no treatment (4 studies).
Participants included in the review
To be eligible, the studies had to include nonsurgical hospital patients. Studies were excluded if the patient population included trauma, pregnant or paediatric patients. Three of the 5 studies giving heparin twice daily included high-risk patients, compared with only two of the 7 trials giving heparin three times daily. The populations of the remaining studies were considered to be moderate risk. Where reported, the mean age of the participants ranged from 58 to 83 years and the proportion of men from 27 to 88%. Settings included general medicine, intensive care units and coronary care units.
Outcomes assessed in the review
To be eligible, the studies had to have an objective assessment of deep venous thrombosis (DVT) (by Doppler compression sonography, impedance plethysmography, radiofibrinogen uptake scanning, autopsy or venography) and pulmonary embolism (PE) (by computed tomography angiography, ventilation perfusion scanning, pulmonary angiogram or autopsy). Studies had to report the incidence of DVT and PE. Other outcomes of interest were bleeding complications. In the included trials, the assessment of thromboembolism was by daily fibrinogen scan (7 studies), ultrasound (3 studies), autopsy (1 study), and D-dimer assessment and venography when positive (1 study).
How were decisions on the relevance of primary studies made?
Two authors independently selected articles for inclusion, with 100% agreement on first review. 
Assessment of study quality
Two investigators independently rated trial quality using the Jadad criteria. Inter-rater agreement was high (kappa 0.97, p=0.0004) and any disagreements were resolved by consensus.
Data extraction
Three reviewers extracted the data independently and any differences were resolved by consensus. The following outcome data were extracted for each article: co-morbidity rates in study population, DVT event rate, PE event rate and bleeding complications (by major and minor bleeding events, where available). All rates (except minor bleeding) were calculated per 1,000 patient-days. The location of DVT was also extracted and, when the studies did not provide enough data to separate proximal from distal DVTs, all DVTs were considered to be proximal. For each trial, patients were stratified as being at high, medium or low risk for DVT according to predefined criteria.
Methods of synthesis
How were the studies combined?
The data were combined statistically in a meta-analysis using a random-effects model (DerSimonian and Laird). Publication bias was assessed using the Shapiro-Wilks normality test.
How were differences between studies investigated?
Heterogeneity was assessed visually with Galbraith plots and with the Mantel-Haenszel Q statistic. Heterogeneity was explored using meta-regression and stratified analyses. As baseline risk was found to be an important factor explaining the variance between studies, meta-regression was used to adjust for these differences when calculating subgroup pvalues. To investigate the impact of the location of embolism on outcomes, two combined PE and DVT outcome groups were analysed: any PE or DVT, and only proximal DVT (popliteal and above) or PE. Sensitivity analyses were carried out to explore the possible dominance of any single study.
Results of the review
Twelve RCTs were included (n=7,978: n=1,664 for three-times-daily heparin treatment and n=6,314 for twice-daily heparin treatment). The numbers of participants in the individual trials ranged from 38 to 5,776.
The Jadad scores for the included trials ranged from 3 to 8. Quality problems included lack of blinding (6 studies), ineffective randomisation (6 studies), inadequate description of withdrawals and drop-outs (5 studies), and inadequate discussion of statistical methods (3 trials).
There were 87 DVTs in the 6,314 patients (5 RCTs) treated with twice-daily heparin, and 36 in the 1,664 patients (7 RCTs) treated with three-times-daily heparin. This corresponded to an event rate of 5.40 per 1,000 patient-days (95% confidence interval, CI: 1.65, 9.15) for twice-daily heparin and 3.01 per 1,000 patient-days (95% CI: 0.68, 5.25) for three-times-daily heparin, after adjustment for baseline risk. There was no significant difference between the treatment schedules.
There were 62 PEs with twice-daily heparin treatment and 8 PEs with three-times-daily heparin. This corresponded to an event rate of 1.50 per 1,000 patient-days (95% CI: 1.12, 1.88) for twice-daily heparin and 0.53 per 1,000 patientdays (95% CI: 0.04, 1.01) for three-times-daily heparin. The difference between the treatments was not statistically significant.
The combined event rates of DVT and PE after adjustment for baseline risk were 5.41 per 1,000 patient-days (95% CI: 2.47, 8.36) for twice-daily heparin and 3.46 per 1,000 patient days (95% CI: 0.97, 5.94) for three-times-daily heparin (no significant difference). For proximal DVT or PE, the event rate (after adjustment for baseline risk) was 2.34 per 1,000 patient-days (95% CI: 1.34, 3.34; 124 events) for twice-daily heparin and 0.86 per 1,000 patient-days (95% CI: 0.30, 1.4; 23 events) for three-times-daily heparin. This difference was statistically significant (p=0.05).
Definitions of bleeding events differed between the studies. The adjusted event rates for minor bleeding were 0.18 per patient (95% CI: -0.16, 0.52) for twice-daily heparin and 0.14 per patient (95% CI: 0.094, 0.184) for three-times-daily
